Projected Costs, Risks, and Benefits of Expanded Newborn Screening for MCADD

@article{Prosser2010ProjectedCR,
  title={Projected Costs, Risks, and Benefits of Expanded Newborn Screening for MCADD},
  author={Lisa A. Prosser and Chung Yin Kong and Donna Rusinak and Susan L Waisbren},
  journal={Pediatrics},
  year={2010},
  volume={125},
  pages={e286 - e294}
}
OBJECTIVE: To evaluate the cost-effectiveness of newborn screening for medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD) incorporating quality-of-life effects for false-positive newborn screens and recommended dietary treatment. METHODS: A computer simulation model was developed to predict costs and health outcomes for expanded newborn screening for MCADD compared with clinical identification. The modeled target population was a hypothetical cohort of 100 000 newborns in the United… 
View on AAP
ncbi.nlm.nih.gov
36 Citations
Highly Influential Citations
4
Background Citations
6

36 Citations

Citation Type

Citation Type

Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State.
Cost-effectiveness of expanded newborn screening in Texas.
  • S. Tiwana, K. Rascati, Haesuk Park
  • Medicine, Political Science
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2012
The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
TLDR
The Washington State cost-benefit models of newborn screening were broadly consistent with peer-reviewed literature, and their findings of net benefit appear to be robust to uncertainty in parameters.
Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France
TLDR
It is concluded that the expansion of the French newborn screening programme to include Medium chain acyl-CoA dehydrogenase deficiency (MCADD) would appear to be cost-effective.
Decision analysis, economic evaluation, and newborn screening: challenges and opportunities
TLDR
The types of data required for the development of decision analysis and cost-effectiveness models for newborn screening programs are outlined and the challenges faced when applying these methods in the arena of newborn screening are discussed.
Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening
TLDR
The application of guidelines for assessing and improving the methodological quality of economic evaluations in newborn screening highlights important issues regarding newborn screening-related economic evaluations, and underscores the need for such issues to be afforded greater consideration in future economic evaluations.
Cost-benefit analysis of Hyperphenylalaninemia Due to 6-Pyruvoyl-Tetrahydropterin Synthase (PTPS) Deficiency: For Consideration of Expanded Newborn Screening in Hong Kong
TLDR
Estimates show that implementation of an expanded newborn screening programme for hyperphenylalaninemias due to 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency in Hong Kong is cost-effective, with a significant annual saving for public expenditure.
Reduction in newborn screening metabolic false-positive results following a new collection protocol
TLDR
A protocol interrupting total parenteral nutrition for 3 h before newborn screening collection resulted in a 74% reduction in false-positive results in a neonatal intensive care unit.
Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis
TLDR
Within the limitations of the present study, extending pre-existing MS/MS newborn screening programmes by GA-I represents a highly cost-effective diagnostic strategy when assessed under conditions comparable to the German health care system.
Health utilities and parental quality of life effects for three rare conditions tested in newborns
BackgroundMeasurement of health utilities is required for economic evaluations. Few studies have evaluated health utilities for rare conditions; even fewer have incorporated disutility that may be…
...
1
2
3
4
...

References

SHOWING 1-10 OF 57 REFERENCES
Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel.
TLDR
In Wisconsin, MS/MS screening for medium-chain acyl-CoA dehydrogenase deficiency alone appears to be cost-effective and future analyses should examine the cost-effectiveness of alternative follow-up and treatment regimens for MCAD and other panel disorders.
Comprehensive Cost-Utility Analysis of Newborn Screening Strategies
TLDR
The results found in the base-case analysis were stable across variations in nearly all variables, and over the long term, funding comprehensive newborn screening programs is likely to save money for society.
Economics of tandem mass spectrometry screening of neonatal inherited disorders
TLDR
Cost-effectiveness analysis using economic modeling indicates that substituting the use of tandem MS for existing technologies for the screening of PKU alone is not economically justified, however, the addition of screening for MCAD deficiency as part of a neonatal screening program for PKU using tandem MS would be economically attractive.
Cost-benefit analysis of universal tandem mass spectrometry for newborn screening.
TLDR
Analysis of costs and benefits resulting from use of MS/MS in screening of 32 000 newborn infants using data from the Kaiser Permanente Medical Care Program of Northern California plus other published data shows costs per quality-adjusted life year saved by MS/ MS screening for inborn errors of metabolism compare favorably with other mass screening programs, including those for breast and prostate cancer.
Quality-Adjusted Life-Years Lack Quality in Pediatric Care: A Critical Review of Published Cost-Utility Studies in Child Health
TLDR
Although there was an increasing tendency for studies to use generic health status classification instruments, choice-based methods, and preferences of the general public, the majority of studies still did not adhere to these standard recommendations even in the period between January 2000 and March 2004.
Parental tolerance of false-positive newborn screening results.
TLDR
Parents have a high tolerance for false-positive newborn screening results and Preferences for test outcomes and other health states associated with screening for metabolic disorders should be included in cost-effectiveness and cost-benefit analyses of expanded newborn screening programs.
Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.
Economic Evaluation in Child Health
  • W. Ungar
  • Medicine, Political Science
  • 2010
TLDR
This book presents detailed discussions of measuring lifetime costs and consequences, capturing productivity losses, obtaining unbiased self- and proxy reports, incorporating externalities, choosing valid outcome measures, assessing utility, and designing studies using value of information.
Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study
Economic Evaluation of Tandem Mass Spectrometry Screening in California
TLDR
It is found that the benefits of MS/MS screening outweighed the costs and that the net benefits were significant and robust in various scenarios with various conservative underlying assumptions.
...
1
2
3
4
5
...